Fluconazole

C difficile risk
Low
Oral Bioavailability
Excellent

Spectrum Of Activity

Dosing

CrCl ≥30 mL/minCrCl <30 mL/min100-400mg PO/IV Q24h50-200mg PO/IV Q24h

Full dose after HD

400-800mg PO/IV Q24h

Loading dose for Candidemia 800mg IV

Serious Infections (e.g. Candidemia, CNS/Endophthalmitis) 400-800mg IV daily

Other indications 100-400mg IV/PO daily

General Information

Candida infections both mucocutaneous and invasive - i.e. Candidemia.

Cryptococcus and Coccidioides infections.

Antifungal prophylaxis in immunocompromised.

Consider QTc monitoring if concomitant drugs affecting the interval or elevated baseline measurement.

  • Drug interactions

  • QTc prolongation

  • Hepatic enzyme abnormalities

  • Rash

  • Alopecia

  • GI upset

Many via CYP450. Suggest review specific patient medications.

Fluconazole increases levels of phenytoin, cyclosporine, tacrolimus, warfarin, oral hypoglycemics.

Risk when combining with other QTc prolonging medications.

Antimicrobial class: Triazole antifungal

Pregnancy category: C

Average serum half life: 20 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Therapeutic

Biliary penetration: Therapeutic